3BORREMAN P, DE LEYN P, DECALUWE H. Morbidity and mortality after induction chemotherapy followed by surgery in II- Ia-N2 non small cell lung cancer[J]. Acta Chit Belg, 2009, 109 (3): 333-339.
4SAKAI Y, OHBAYASHI C, KANOMATA N. et al. Significance of microscopic invasion into hilar peribronchovascular soft tissue in resection specimens of primary non-small cell lung cancer[J]. Lung Cancer, 2011, 73(1): 89-95.
5PAN XF, CAO K J, DI JF. Analysis of early postoperative com- plications in elder patients with lung cance underging sleeve re- section or pneumonectomy[J]. Journal of Shanghai Jiaotong Uni- versity, 2011,31(3):331-333. Chinese.
6RIAZ S, P LINKLATER K, M PAGE R, et al. Recent trends in resection rates among non-small cell lung cancer patients in England[J]. Thorax, 2012, 67(9): 811-814.
7EICHHORN F, STORZ K, HOFFMANN H, et al. Sleeve pneu- monectomy for central non-small cell lung cancer: indications, complications, and survival[J]. Ann Thorac Surg, 2013, 96(1): 253-258.
8KIM AW, LIPTAY MJ, BONOM! P, et al. Neoadjuvant chemora- diation for clinically advanced non-small cell lung cancer: an analysis of 233 patients[J]. Ann Thorac Surg, 2011, 92(1): 233- 241.
9Janke M, Peeters B,de Leeuw 0, et al. Recombinant New-castle disease virus ( NDV) with inserted gene coding forGM-CSF as a new vector for cancer immunogene therapy[J]. Gene Therapy, 2007, 14: 1639-1649.
10Ge J, Wang X, Tao L, et al. Newcastle disease virus-vec-tored rabies vaccine is safe, highly immunogenic, and pro-vides long-lasting protection in dogs and cats. [ J] ? J Virol,2011, 85: 8241-8252.
